Emergent BioSolutions (NYSE:EBS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Emergent BioSolutions’ Q1 2025 earnings at $0.27 EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.32 EPS and FY2026 earnings at $3.83 EPS.

A number of other equities analysts also recently weighed in on the company. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Monday, February 17th. Benchmark increased their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Up 0.6 %

NYSE EBS opened at $5.84 on Tuesday. The stock has a fifty day moving average of $9.38 and a 200-day moving average of $9.00. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a 52 week low of $1.82 and a 52 week high of $15.10. The stock has a market capitalization of $316.22 million, a P/E ratio of -1.42 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the previous year, the company earned ($0.77) EPS. On average, equities research analysts forecast that Emergent BioSolutions will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Emergent BioSolutions

Several hedge funds have recently bought and sold shares of the stock. State Street Corp raised its stake in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after purchasing an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP acquired a new stake in shares of Emergent BioSolutions during the third quarter worth $9,296,000. Millennium Management LLC grew its holdings in Emergent BioSolutions by 83.0% during the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after acquiring an additional 671,947 shares during the period. Invesco Ltd. grew its stake in Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after purchasing an additional 638,995 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after buying an additional 444,790 shares during the period. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.